Full Press Release Details
BIOLOGICS COMPLETES $500,000 OF FINANCING
MA (March 29, 2018) - Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international
spine fusion markets, announced today the completion of $500,000 funding with Orthofix Holding, Inc. The funding represents the
second round of a previously announced private placement.
securities offered have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the
United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable
state securities laws.
Biologics (OTCQB:BBLG) was founded to pursue regenerative medicine for bone.
Biologics Corporation is undertaking groundbreaking work with the three founders and select strategic partners, building on unprecedented
research on the Nell-1 molecule that has produced a significant number of studies and publications in peer reviewed scientific
literature. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration
in spinal fusion. Nell-1 is a recombinant human protein growth factor that is essential for normal bone development.
more information, please visit the company's website at www.bonebiologics.com.
Biologics trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies. OTCQB
companies are current in their reporting and undergo an annual verification and management certification process. Investors can
find Real-Time quotes and market information for the company on www.otcmarkets.com.
press release contains forward-looking statements that reflect the Company's current beliefs, expectations or intentions
regarding future events. Any statements contained in this press release that are not statements of historical fact may be deemed
forward-looking statements. Words such as "will," "will be," "anticipate," "predict,"
"continue," "future," and similar expressions are intended to identify such forward-looking statements.
communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of
a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.